16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
- Autores
- López Torres, Manuel Othoniel; Marquina Castillo, Brenda; Ramos Espinosa, Octavio; Mata Espinosa, Dulce; Barrios Payan, Jorge A.; Baay Guzman, Guillermina; Huerta Yepez, Sara; Bini, Estela Isabel; Torre Villalvazo, Ivan; Torres, Nimbe; Tovar, Armando; Chamberlin, William; Ge, Yu; Carranza, Maria Andrea; Hernández Pando, Rogelio
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1). 11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv. Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular effects of BEA were associated with a reduction in hyperglycemia and liver steatosis, lower lung bacillary loads and pneumonia. These results uphold BEA as a promising effective therapy for the T2D/TB co-morbidity.
Fil: López Torres, Manuel Othoniel. Instituto Nacional de la Nutrición Salvador Zubiran; México
Fil: Marquina Castillo, Brenda. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Ramos Espinosa, Octavio. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Mata Espinosa, Dulce. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Barrios Payan, Jorge A.. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Baay Guzman, Guillermina. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Huerta Yepez, Sara. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Bini, Estela Isabel. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Torre Villalvazo, Ivan. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Torres, Nimbe. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Tovar, Armando. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Chamberlin, William. No especifíca;
Fil: Ge, Yu. No especifíca;
Fil: Carranza, Maria Andrea. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; Argentina
Fil: Hernández Pando, Rogelio. Instituto Nacional de Ciencias Medicas y Nutricion; México - Materia
-
11-ΒHSD1
ACTIVE GLUCOCORTICOIDS
BEA
CENTRAL NERVOUS SYSTEM
COLONY-FORMING UNITS
DIABETES–TUBERCULOSIS CO-MORBIDITY
IMMUNOTHERAPY - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/182410
Ver los metadatos del registro completo
id |
CONICETDig_8e28cfeb2f9015c3e39864db2c742a58 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/182410 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatmentLópez Torres, Manuel OthonielMarquina Castillo, BrendaRamos Espinosa, OctavioMata Espinosa, DulceBarrios Payan, Jorge A.Baay Guzman, GuillerminaHuerta Yepez, SaraBini, Estela IsabelTorre Villalvazo, IvanTorres, NimbeTovar, ArmandoChamberlin, WilliamGe, YuCarranza, Maria AndreaHernández Pando, Rogelio11-ΒHSD1ACTIVE GLUCOCORTICOIDSBEACENTRAL NERVOUS SYSTEMCOLONY-FORMING UNITSDIABETES–TUBERCULOSIS CO-MORBIDITYIMMUNOTHERAPYhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1). 11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv. Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular effects of BEA were associated with a reduction in hyperglycemia and liver steatosis, lower lung bacillary loads and pneumonia. These results uphold BEA as a promising effective therapy for the T2D/TB co-morbidity.Fil: López Torres, Manuel Othoniel. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Marquina Castillo, Brenda. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Ramos Espinosa, Octavio. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Mata Espinosa, Dulce. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Barrios Payan, Jorge A.. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Baay Guzman, Guillermina. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Huerta Yepez, Sara. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Bini, Estela Isabel. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Torre Villalvazo, Ivan. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Torres, Nimbe. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Tovar, Armando. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Chamberlin, William. No especifíca;Fil: Ge, Yu. No especifíca;Fil: Carranza, Maria Andrea. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; ArgentinaFil: Hernández Pando, Rogelio. Instituto Nacional de Ciencias Medicas y Nutricion; MéxicoWiley Blackwell Publishing, Inc2021-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/182410López Torres, Manuel Othoniel; Marquina Castillo, Brenda; Ramos Espinosa, Octavio; Mata Espinosa, Dulce; Barrios Payan, Jorge A.; et al.; 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment; Wiley Blackwell Publishing, Inc; Clinical and Experimental Immunology; 205; 2; 4-2021; 232-2450009-9104CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/cei.13603info:eu-repo/semantics/altIdentifier/doi/10.1111/cei.13603info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:34:19Zoai:ri.conicet.gov.ar:11336/182410instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:34:20.167CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment |
title |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment |
spellingShingle |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment López Torres, Manuel Othoniel 11-ΒHSD1 ACTIVE GLUCOCORTICOIDS BEA CENTRAL NERVOUS SYSTEM COLONY-FORMING UNITS DIABETES–TUBERCULOSIS CO-MORBIDITY IMMUNOTHERAPY |
title_short |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment |
title_full |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment |
title_fullStr |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment |
title_full_unstemmed |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment |
title_sort |
16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment |
dc.creator.none.fl_str_mv |
López Torres, Manuel Othoniel Marquina Castillo, Brenda Ramos Espinosa, Octavio Mata Espinosa, Dulce Barrios Payan, Jorge A. Baay Guzman, Guillermina Huerta Yepez, Sara Bini, Estela Isabel Torre Villalvazo, Ivan Torres, Nimbe Tovar, Armando Chamberlin, William Ge, Yu Carranza, Maria Andrea Hernández Pando, Rogelio |
author |
López Torres, Manuel Othoniel |
author_facet |
López Torres, Manuel Othoniel Marquina Castillo, Brenda Ramos Espinosa, Octavio Mata Espinosa, Dulce Barrios Payan, Jorge A. Baay Guzman, Guillermina Huerta Yepez, Sara Bini, Estela Isabel Torre Villalvazo, Ivan Torres, Nimbe Tovar, Armando Chamberlin, William Ge, Yu Carranza, Maria Andrea Hernández Pando, Rogelio |
author_role |
author |
author2 |
Marquina Castillo, Brenda Ramos Espinosa, Octavio Mata Espinosa, Dulce Barrios Payan, Jorge A. Baay Guzman, Guillermina Huerta Yepez, Sara Bini, Estela Isabel Torre Villalvazo, Ivan Torres, Nimbe Tovar, Armando Chamberlin, William Ge, Yu Carranza, Maria Andrea Hernández Pando, Rogelio |
author2_role |
author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
11-ΒHSD1 ACTIVE GLUCOCORTICOIDS BEA CENTRAL NERVOUS SYSTEM COLONY-FORMING UNITS DIABETES–TUBERCULOSIS CO-MORBIDITY IMMUNOTHERAPY |
topic |
11-ΒHSD1 ACTIVE GLUCOCORTICOIDS BEA CENTRAL NERVOUS SYSTEM COLONY-FORMING UNITS DIABETES–TUBERCULOSIS CO-MORBIDITY IMMUNOTHERAPY |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1). 11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv. Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular effects of BEA were associated with a reduction in hyperglycemia and liver steatosis, lower lung bacillary loads and pneumonia. These results uphold BEA as a promising effective therapy for the T2D/TB co-morbidity. Fil: López Torres, Manuel Othoniel. Instituto Nacional de la Nutrición Salvador Zubiran; México Fil: Marquina Castillo, Brenda. Instittuto de Ciencias Médicas y Nutrición; México Fil: Ramos Espinosa, Octavio. Instittuto de Ciencias Médicas y Nutrición; México Fil: Mata Espinosa, Dulce. Instittuto de Ciencias Médicas y Nutrición; México Fil: Barrios Payan, Jorge A.. Instittuto de Ciencias Médicas y Nutrición; México Fil: Baay Guzman, Guillermina. Instittuto de Ciencias Médicas y Nutrición; México Fil: Huerta Yepez, Sara. Instittuto de Ciencias Médicas y Nutrición; México Fil: Bini, Estela Isabel. Instittuto de Ciencias Médicas y Nutrición; México Fil: Torre Villalvazo, Ivan. Instittuto de Ciencias Médicas y Nutrición; México Fil: Torres, Nimbe. Instittuto de Ciencias Médicas y Nutrición; México Fil: Tovar, Armando. Instittuto de Ciencias Médicas y Nutrición; México Fil: Chamberlin, William. No especifíca; Fil: Ge, Yu. No especifíca; Fil: Carranza, Maria Andrea. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; Argentina Fil: Hernández Pando, Rogelio. Instituto Nacional de Ciencias Medicas y Nutricion; México |
description |
Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1). 11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv. Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular effects of BEA were associated with a reduction in hyperglycemia and liver steatosis, lower lung bacillary loads and pneumonia. These results uphold BEA as a promising effective therapy for the T2D/TB co-morbidity. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-04 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/182410 López Torres, Manuel Othoniel; Marquina Castillo, Brenda; Ramos Espinosa, Octavio; Mata Espinosa, Dulce; Barrios Payan, Jorge A.; et al.; 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment; Wiley Blackwell Publishing, Inc; Clinical and Experimental Immunology; 205; 2; 4-2021; 232-245 0009-9104 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/182410 |
identifier_str_mv |
López Torres, Manuel Othoniel; Marquina Castillo, Brenda; Ramos Espinosa, Octavio; Mata Espinosa, Dulce; Barrios Payan, Jorge A.; et al.; 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment; Wiley Blackwell Publishing, Inc; Clinical and Experimental Immunology; 205; 2; 4-2021; 232-245 0009-9104 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/cei.13603 info:eu-repo/semantics/altIdentifier/doi/10.1111/cei.13603 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613061363630080 |
score |
13.070432 |